Your browser is no longer supported. Please, upgrade your browser.
Zai Lab Limited
Index- P/E- EPS (ttm)-3.46 Insider Own1.18% Shs Outstand81.49M Perf Week24.45%
Market Cap14.49B Forward P/E- EPS next Y-2.52 Insider Trans-9.99% Shs Float60.23M Perf Month24.02%
Income-268.90M PEG- EPS next Q-1.58 Inst Own66.20% Short Float3.30% Perf Quarter-3.84%
Sales49.00M P/S295.76 EPS this Y-14.20% Inst Trans7.66% Short Ratio4.35 Perf Half Y86.04%
Book/sh14.35 P/B11.45 EPS next Y31.00% ROA-41.50% Target Price192.11 Perf Year158.91%
Cash/sh13.46 P/C12.21 EPS next 5Y- ROE-47.50% 52W Range58.59 - 193.54 Perf YTD21.42%
Dividend- P/FCF- EPS past 5Y-56.80% ROI-25.80% 52W High-15.09% Beta1.13
Dividend %- Quick Ratio12.30 Sales past 5Y- Gross Margin65.80% 52W Low180.47% ATR7.89
Employees692 Current Ratio12.40 Sales Q/Q773.50% Oper. Margin- RSI (14)66.63 Volatility4.94% 5.28%
OptionableYes Debt/Eq0.00 EPS Q/Q-25.90% Profit Margin- Rel Volume1.11 Prev Close164.29
ShortableYes LT Debt/Eq0.00 EarningsMar 01 BMO Payout- Avg Volume456.58K Price164.33
Recom1.50 SMA2019.56% SMA5010.03% SMA20044.99% Volume504,660 Change0.02%
Apr-28-20Initiated Goldman Buy
Apr-15-20Initiated Guggenheim Buy $75
Jul-12-19Initiated BofA/Merrill Buy
Jul-05-19Initiated Macquarie Outperform
Jan-29-19Initiated Credit Suisse Outperform
Nov-21-18Initiated Jefferies Buy
Jun-21-18Resumed Leerink Partners Outperform $43
Feb-14-18Upgrade JP Morgan Neutral → Overweight
Oct-16-17Initiated Leerink Partners Outperform $42
Oct-16-17Initiated JP Morgan Neutral $32
Apr-19-21 04:05PM  
Apr-14-21 11:44AM  
Apr-13-21 07:37AM  
Apr-06-21 11:46AM  
Mar-31-21 04:57AM  
Mar-12-21 11:54AM  
Mar-04-21 04:19PM  
Mar-02-21 11:56PM  
Mar-01-21 07:00AM  
Feb-27-21 09:23AM  
Feb-18-21 07:31AM  
Jan-28-21 07:30AM  
Jan-11-21 06:45AM  
Jan-06-21 04:01PM  
Dec-30-20 07:30AM  
Dec-29-20 08:09AM  
Dec-28-20 07:00PM  
Dec-16-20 08:15PM  
Dec-01-20 07:30AM  
Nov-11-20 08:30AM  
Nov-10-20 07:00PM  
Oct-29-20 07:30AM  
Oct-28-20 03:18PM  
Oct-09-20 08:48AM  
Oct-06-20 07:30AM  
Oct-05-20 07:30AM  
Sep-28-20 08:35PM  
Sep-27-20 11:26PM  
Sep-22-20 07:53AM  
Sep-19-20 07:30AM  
Sep-17-20 05:30AM  
Sep-16-20 07:15AM  
Sep-10-20 09:18AM  
Sep-03-20 07:30AM  
Aug-31-20 07:30AM  
Aug-19-20 10:26AM  
Aug-17-20 07:30AM  
Aug-13-20 08:00PM  
Aug-04-20 07:30AM  
Aug-02-20 09:08AM  
Jul-30-20 07:30AM  
Jul-20-20 10:39AM  
Jul-16-20 06:31PM  
Jul-07-20 11:37PM  
Jun-17-20 02:03PM  
May-28-20 07:05PM  
May-27-20 07:30AM  
May-18-20 09:45PM  
May-13-20 10:10AM  
May-11-20 11:14AM  
May-08-20 01:18PM  
May-06-20 07:30AM  
Apr-30-20 07:30AM  
Apr-16-20 07:30AM  
Apr-08-20 06:00AM  
Mar-28-20 09:09PM  
Mar-19-20 12:21PM  
Mar-16-20 07:30AM  
Mar-05-20 07:30AM  
Feb-11-20 07:30AM  
Feb-10-20 07:30AM  
Feb-04-20 07:30AM  
Jan-27-20 04:30PM  
Jan-22-20 09:43PM  
Jan-21-20 04:34PM  
Jan-14-20 07:30AM  
Jan-09-20 07:30AM  
Dec-30-19 06:55AM  
Dec-27-19 08:46AM  
Dec-23-19 07:30AM  
Dec-16-19 07:30AM  
Dec-08-19 06:26PM  
Oct-30-19 07:30AM  
Oct-27-19 04:16PM  
Oct-25-19 08:30AM  
Oct-24-19 08:30AM  
Oct-04-19 07:30AM  
Sep-29-19 02:15PM  
Sep-11-19 12:22PM  
Sep-03-19 06:01PM  
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops, and commercializes therapeutics to treat oncology, autoimmune, and infectious diseases in China. The company offers ZEJULA for the treatment of breast cancer and non-small cell lung cancer (NSCLC); and Optune, a cancer therapy to treat glioblastoma multiforme. It also develops QINLOCK for the treatment of gastrointestinal stromal tumors; Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naive- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Bemarituzumab for the treatment of gastric and gastroesophageal junction cancer; and Omadacycline to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Efgartigimod to reduce disease-causing immunoglobulin G (IgG) antibodies; Retifanlimab to treat microsatellite instability high endometrial cancer; ZL-2309 for the treatment of metastatic pancreatic cancer, metastatic colorectal cancer, and other advanced solid tumors; ZL-1201 to treat solid tumors and hematological malignancies; ZL-1102 for the treatment of psoriasis; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited has license and collaboration agreements with the GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Du YingChairwoman & CEOApr 07Sale134.4221,9362,948,655897,541Apr 07 07:55 PM
Du YingChairwoman & CEOApr 06Sale127.2838,3924,886,566919,477Apr 07 07:55 PM
Du YingChairwoman & CEOApr 05Sale126.1950,7846,408,461957,869Apr 07 07:55 PM
Fu TaoPresident & COOMar 26Option Exercise18.9220,000378,400207,000Mar 30 06:48 PM
Chen Kai-XianDirectorMar 12Sale142.534,302613,16424,662Mar 30 08:51 PM